Cellexa

Cellexa (also referred to as Celexa in some contexts) is an investigational gene therapy candidate developed by Cellastra for scar prevention and wound healing. It utilizes a proprietary triple-mutant adeno-associated virus 6.2FF (AAV6.2FF) vector, licensed from the University of Guelph, to deliver a transgene encoding ensereptide (a 25-amino acid peptide derived from human lactoferrin) as an ensereptide-Fc fusion protein. Designed for localized, long-term in vivo expression, Cellexa aims to provide continuous production of the anti-scarring peptide at the site of injury for weeks or months, exerting anti-inflammatory, anti-scarring, and anti-bacterial effects. Cellexa is in preclinical (IND-enabling) development. Cellastra is developing different formulations of this gene therapy platform, including Scarlexa (a dermal formulation for preventing scarring and adhesions after surgery or burn injuries) and Fibrexa (an inhaled formulation for preventing pulmonary fibrosis and respiratory complications).

Other names

CELLEXACelexaensereptide-Fc fusion protein gene therapy